<DOC>
	<DOC>NCT03062787</DOC>
	<brief_summary>It is a post-license, multicenter, randomized, single blind, controlled study comparing a single injection of Cingal® (study arm) with a single injection of Monovisc® (control arm).</brief_summary>
	<brief_title>Early Effect of Cingal® Compared to Monovisc® in Patients With Osteoarthritis of the Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Age &gt; 18 years of age Diagnosed with osteoarthritis of the knee Candidate for an intraarticular injection (single joint, unilateral) of Monovisc® or Cingal® as part of their routine clinical care and in accordance with the locally approved label Previous intraarticular injection within the last 6 months from enrolment Known hypersensitivity to corticosteroids, hyaluronic acid or any component of Cingal® or Monovisc® Infectious, traumatic or neoplasic component of knee pathology Surgery of the knee within the last 6 months or scheduled surgery in the next two months from enrolment Patients with impaired cardiorenal function, endocrine, or other diseases or conditions that use of corticosteroid is warned. Patients with known bleeding disorders Patient currently treated with oral steroids or opioids Patients that, in the investigators' opinion, are unlikely to comply with protocol Pregnant or nursing women or women who suspect they might be pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>